Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12574MR)

This product GTTS-WQ12574MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ12574MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1276MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ3370MR IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AT-004
GTTS-WQ12491MR IVTScrip™ mRNA-Anti-MUC5AC, NOE-102(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NOE-102
GTTS-WQ8862MR IVTScrip™ mRNA-Anti-MS4A1, IDEC-C2B8(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IDEC-C2B8
GTTS-WQ15000MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ3763MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ4003MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BGB-A317
GTTS-WQ9258MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMMU-130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW